Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | President Myriad Oncology | September 30, 2018 | October 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date September 30, 2018 · Filed October 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,195 |
Ending reported balance
After 2018-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-09-30 · Disposition to issuer · Disposed 629 · Balance 36,824 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Row 2 · 2018-09-30 · Disposition to issuer · Disposed 629 · Balance 36,195 F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2018 Filed Oct 2, 2018 13:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 629 | $46.00 | $28,934.00 |
DisclosureSEC source: 0001349943-18-000012 · edgardoc.xml · nonDerivative · entry 2 Sanders Walter Lloyd · CIK 0001349943 · President Myriad Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,195 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 13:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 629 | $46.00 | $28,934.00 |
DisclosureSEC source: 0001349943-18-000012 · edgardoc.xml · nonDerivative · entry 1 Sanders Walter Lloyd · CIK 0001349943 · President Myriad Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,824 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2018 Filed Sep 26, 2018 18:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 1,664 | $46.65 | $77,625.60 |
DisclosureSEC source: 0001349943-18-000010 · edgardoc.xml · nonDerivative · entry 1 Sanders Walter Lloyd · CIK 0001349943 · President Myriad Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,453 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 18:26 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 844 | $46.35 | $39,119.40 |
DisclosureSEC source: 0001349943-18-000008 · edgardoc.xml · nonDerivative · entry 1 Sanders Walter Lloyd · CIK 0001349943 · President Myriad Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,117 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.